Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Mucinex maker Reckitt Beckiser’s new “simpler and more effective organization” won’t include 190 New Jersey workers. | ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere, the Dow ...

In the 7th International Symposium on GnRH Analogs in Cancer and Human Reproduction, Organon presented new techniques of development of fertility In the 7th International Symposium on GnRH Analogs ...

In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three ...

Morgan Stanley lowered the firm’s price target on Organon (OGN) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm ...

JERSEY CITY, N.J., April 15, 2025--Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025. JERSEY CITY, N ...